Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis

Pharmacogenomics Journal

Volumn 8, Issue 3, 2008, Pages 186-195

  Kindmark, A ^a   Jawaid, A ^b   Harbron, C G ^b   Barratt, B J ^b   Bengtsson, O F ^a   Andersson, T B ^a   Carlsson, S ^a   Cederbrant, K E ^c   Gibson, N J ^b   Armstrong, M ^b   Lagerstrom Fermer M E ^a   Dellsen A ^a   Brown, E M ^b   Thornton, M ^b   Dukes, C ^b   Jenkins, S C ^b   Firth, M A ^b   Harrod, G O ^b   Pinel, T H ^b   Billing Clason, S M E ^a   Cardon, L R ^d   March, R E ^b   more..

^a ASTRAZENECA R AND D   (Sweden)

^b ASTRAZENECA   (United Kingdom)

^c ASTRAZENECA R AND D   (Sweden)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN B; ARYLDIALKYLPHOSPHATASE 1; CHIMERIN; DRUG METABOLITE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MELAGATRAN; RETINOID X RECEPTOR GAMMA; XIMELAGATRAN;

ADAPTIVE IMMUNITY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLELE; ARTICLE; BINDING AFFINITY; CLINICAL TRIAL; CONTROLLED STUDY; GENE IDENTIFICATION; GENE REPLICATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOME ANALYSIS; HUMAN; IMMUNOPATHOGENESIS; LIVER INJURY; LONG TERM EXPOSURE; MAJOR CLINICAL STUDY; PHARMACOGENETICS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOEMBOLISM;

ALANINE TRANSAMINASE; ANTICOAGULANTS; AZETIDINES; BENZYLAMINES; CASE-CONTROL STUDIES; HLA-DQ ANTIGENS; HLA-DR ANTIGENS; HUMANS; LIVER; LYMPHOCYTE ACTIVATION; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES;

EID: 44049102035     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500458     Document Type: Article

References (31)

1. Lee WM, Larrey D, Olsson R, Lewis JH, Keisu M, Auclert L et al. Hepatic findings in long-term clinical trials of ximelagatran. Drug Safety 2005; 28: 351-370.
2. Harenberg J, Jörg I, Weiss C. Observations of alanine aminotransferase and aspartate aminotransferase in THRIVE studies treated orally with ximelagatran. Int J Toxicol 2006; 25: 165-169.
3. AstraZeneca Decides to Withdraw Exanta™ http://www.astrazeneca.com/ pressrelease/5217.aspx.
4. Hinds DA, Stuve LL, Nilsen GB, Halperin E, Eskin E, Ballinger DG et al. Whole-genome patterns of common DNA variation in three human populations. Science 2005; 307: 1072-1079.
5. Storey JD. A direct approach to false discovery rates. J R Stat Soc B 2001; 64: 479-498.
6. Yunis EJ, Larsen CE, Fernandez-Vina M, Awdeh ZL, Romero T, Hansen JA et al. Inheritable variable sizes of DNA stretches in the human MHC conserved extended haplotypes and their fragments or blocks. Tissue Antigens 2003; 62: 1-20.
7. Miretti MM, Walsh EC, Ke X, Delgado M, Griffiths M, Hunt S et al. A high-resolution linkage-disequilibrium map of the human major histocompatibility complex and first generation of tag single-nucleotide polymorphisms. Am J Hum Genet 2005; 76: 634-646.
8. Maria VAJ, Victorino RMM. Diagnostic value of specific T-cell reactivity to drugs in 95 cases of drug induced liver injury. Gut 1997; 41 534-540.
9. De Groot AS. Immunomics: Discovering new targets for vaccines and therapeutics. Drug Discov Today 2006; 11: 203-209.
10. Gibert M, Sanchez-Mazas A. Geographic patterns of functional categories of HLA-DRB1 alleles: A new approach to analyse associations between HLA-DRB1 and disease. Eur J Immunogenet 2003; 30: 361-374.
11. Berlin M, Fogdell-Hahn A, Olerup O, Eklund A, Grunewald J. HLA-DR predicts the prognosis in Scandinavian patients with pulmonary sarcoidosis. Am J Respir Crit Care Med 1997; 156: 1601-1605.
12. Vergani D, Mieli-Vergani G. Autoimmune hepatitis. Minerva Gastroenterol Dietol 2004; 50: 113-123.
13. Sharma SK, Balamurugan A, Saha PK, Pandey RM, Mehra NK. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med 2002; 166: 916-919.
14. Holt MP, Ju C. Mechanisms of drug-induced liver injury. AAPS J 2006; 8: E48-E54.
15. Castell JV. Allergic hepatitis: A drug-mediated organ-specific immune reaction. Clin Exp Allergy 1998; 28(Suppl 4): 13-19.
16. Pichler WJ. Pharmacological interaction of drugs with antigen-specific immune receptors: The p-i concept. Curr Opin Allergy Clin Immunol 2002; 2: 301-305.
17. Gerber BO, Pichler WJ. Noncovalent interactions of drugs with immune receptors may mediate drug-induced hypersensitivity reactions. AAPS J 2006; 8: E160-E165.
18. Britschi M, von Greyerz S, Burkhart C, Pichler WJ. Molecular aspects of drug recognition by specific T cells. Curr Drug Targets 2003; 4 1-11.
19. Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M et al Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004; 22: 1382-1388.
20. Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: Proposal for a new dosing regimen. Blood 2005; 106: 2329-2333.
21. Rauch A, Nolan D, Martin A, McKinnon E, Almeida C, Mallal S. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin Infect Dis 2006; 43: 99-102.
22. Pirmohamed M, Park BK. Genetic susceptibility to adverse drug reactions. Trends Pharmacol Sci 2001; 22: 298-305.
23. March R. Challenges and opportunities of pharmacogenetics in drug development. Pers Med 2006; 3: 195-206.
24. Carlson CS, Eberle MA, Rieder MJ, Yi Q, Kruglyak L, Nickerson DA. Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet 2004; 74: 106-120.
25. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B et al. The structure of haplotype blocks in the human genome. Science 2002; 296: 2225-2229.
26. Traherne JA, Horton R, Roberts AN, Miretti MM, Hurles ME, Stewart CA et al. Genetic analysis of completely sequenced disease-associated MHC haplotypes identifies shuffling of segments in recent human history. PLoS Genet 2006; J2: E9.
27. Gual L, Martinez A, Fernandez-Arquero M, Garcia-Rodriguez MC, Ferreira A, Fontan G et al. Major histocompatibility complex haplotypes in Spanish immunoglobulin A deficiency patients: A comparative fine mapping microsatellite study. Tissue Antigens 2004; 64: 671-677.
28. Sham PC, Curtis D. Monte Carlo tests for associations between disease and alleles at highly polymorphic loci. Ann Hum Genet 1995; 59 97-105.
29. Devlin B, Bacanu S-A, Roeder K. Genomic control to the extreme. Nat Genet 2004; 36: 1129-1130.
30. Pritchard JK, Stephens M, Donnely P. Inference of population structure using multilocus genotype data. Genetics 2000; 155: 945-959.
31. Nyfeler B, Pichler WJ. The lymphocyte transformation test for the diagnosis of drug allergy: Sensitivity and specificity. Clin Exp Allergy 1997; 27: 175-181.